Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer April 12, 2022
Sitryx Licenses Intellectual Property Rights for Inhibitors of a New Target in Immunometabolism from Cancer Research UK in Exclusive Worldwide Agreement July 12, 2021
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines March 31, 2020
